NFKB1 and type 2 diabetes mellitus: As NFκB signalling is the central pathway for inflammatory processes, enriched pathway, ‘RANKL/RANK (Receptor activator of NFKB (ligand) signalling Pathway’ points towards the role of inflammation in both the lipodystrophy and type 2 diabetes.